Replay and Syena license NIH library of TCRs targeting cancer neoantigens
Dec. 20, 2023
Replay Holdings LLC has entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) for intellectual property related to a library of T-cell receptors (TCRs) directed against multiple cancer neoantigens.